Influence of Early Wound Healing on the Outcomes of Regenerative Periodontal Surgery (EWH_reg)

June 28, 2026 updated by: Andrea Pilloni MD DDS MS, University of Roma La Sapienza

Influence of Early Wound Healing on the 12-month Clinical and Radiographic Outcomes of Regenerative Periodontal Surgery: a Prospective Observational Cohort Study

This study investigates whether early post-surgical healing (1-2 weeks) affects the 12-month clinical and radiographic success of periodontal regenerative therapy in patients with Stage III-IV periodontitis.

Study Overview

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Rome
      • Rome, Rome, Italy, 00161
        • Recruiting
        • Sapienza University of Rome, Department of Oral and Maxillofacial Sciences, Section of Periodontology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult patients (ages 18-75) diagnosed with Stage III or IV Periodontitis according to the 2017 World Workshop Classification. These patients present with at least one deep interproximal infrabony defect requiring regenerative surgical treatment. Participants are recruited from the patient pool of the Section of Periodontics at Sapienza University of Rome, Italy. The population includes both systemically healthy individuals and those with well-controlled systemic conditions (ASA I or II), who have maintained optimal oral hygiene (FMPS/FMBS < 15%) following initial non-surgical periodontal therapy.

Description

Inclusion Criteria:

  • Diagnosis of Stage III or IV Periodontitis.
  • Presence of at least one deep interproximal infrabony defect (Probing Pocket Depth [PPD] >= mm, radiographic depth >= 3 mm).
  • Optimal oral hygiene: Full-Mouth Plaque Score (FMPS) and Full-Mouth Bleeding Score (FMBS) < 15% at the time of surgery.

Exclusion Criteria:

  • Systemic: ASA III-VI classification; uncontrolled diabetes; medications causing gingival overgrowth (e.g., nifedipine, cyclosporine, phenytoin); heavy smokers (>10 cigarettes/day); pregnancy or lactation.
  • Local: Third molars; Grade III tooth mobility; inadequate endodontic treatment; teeth undergoing orthodontic treatment; teeth supporting removable or implant-linked fixed prosthetics.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Periodontal Regeneration Cohort
his single cohort consists of patients with Stage III-IV periodontitis presenting at least one deep vertical infrabony defect. All patients receive periodontal regenerative surgery according to clinical indications. The cohort will be subsequently stratified into subgroups during data analysis based on their Early Wound Healing Index (EHI) scores at 1 and 2 weeks to evaluate the impact of healing quality on 12-month clinical attachment level (CAL) and radiographic outcomes.
All subjects undergo surgical debridement of the infrabony defect followed by a regenerative approach (biologics, bone grafts, or blood clot alone) using papilla preservation techniques (MIST, M-MIST, MPPT, SPPF, or SFA).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Clinical Attachment Level (CAL).
Time Frame: Baseline, 6 months, and 12 months.
Baseline, 6 months, and 12 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Early wound healing Classification
Time Frame: 1 and 2 weeks
This system categorizes wounds into Classes (I-III) and Subclasses (A-C). The Classes define the wound closure status, with Class I indicating complete closure, Class II representing partial closure, and Class III denoting an open wound. The Subclasses assess the quality of healing by evaluating clinical signs during the hemostatic and inflammatory phase and the proliferative phase. Subclass A reflects optimal healing, Subclass B indicates sub-optimal healing, and Subclass C describes complicated healing.
1 and 2 weeks
Probing Pocket Depth (PPD) Change:
Time Frame: Baseline, 6 months, and 12 months.
Baseline, 6 months, and 12 months.
Early Wound Healing Index (EHI)
Time Frame: 1 and 2 weeks
Assessed using the Early Wound Healing Index (EHI) by Wachtel et al. The index ranges from a minimum score of 1 (complete tissue closure without fibrin) to a maximum score of 5 (incomplete tissue closure with partial/complete necrosis). Higher scores mean a worse clinical outcome.
1 and 2 weeks
Change in Radiographic Linear Bone Fill
Time Frame: Baseline, 6 months, and 12 months.
Measured in millimeters (mm) on standardized radiographs from baseline to 6 and 12 months. It calculates the distance from a fixed reference point (e.g., cementoenamel junction) to the bottom of the bony defect. A positive change (increase in mm) indicates bone gain (better outcome).
Baseline, 6 months, and 12 months.
Oral Health Impact Profile-14 questionnaire
Time Frame: 1 and 2 weeks
Evaluation of oral health-related quality of life using the unabbreviated Oral Health Impact Profile-14 (OHIP-14) questionnaire. The total score ranges from a minimum of 0 to a maximum of 56. Higher scores mean a worse outcome (greater negative impact on quality of life).
1 and 2 weeks
Number of analgesic tablets
Time Frame: 1 and 2 weeks
1 and 2 weeks
Patient-Reported Postoperative Swelling as Assessed by a Visual Analog Scale (VAS)
Time Frame: 1 and 2 weeks
Postoperative swelling evaluated by the patient using a 100-mm Visual Analog Scale (VAS). The scale ranges from 0 mm (no swelling) to 100 mm (severe swelling). Higher scores indicate worse outcomes (greater swelling).
1 and 2 weeks
Percentage of Sites With Bleeding on Probing (BOP)
Time Frame: Baseline, 6 months and 12 months
Presence or absence of bleeding assessed within 30 seconds of probing at specific sites. The data will be aggregated and reported as the percentage of sites showing bleeding out of the total sites examined. Higher percentages indicate worse outcomes.
Baseline, 6 months and 12 months
Postoperative Pain/Discomfort as Assessed by a Visual Analog Scale (VAS)
Time Frame: 1 and 2 weeks
Patient's self-reported surgical discomfort/pain measured using a 100-mm Visual Analog Scale (VAS). The scale ranges from 0 mm (no pain/discomfort) to 100 mm (worst possible pain). Higher scores indicate worse outcomes.
1 and 2 weeks
Patient-Reported Postoperative Estethics as Assessed by a Visual Analog Scale (VAS)
Time Frame: 1 and 2 weeks
Patient's self-reported estethics measured using a 100-mm Visual Analog Scale (VAS). The scale ranges from 0 mm (worst possible estethics) to 100 mm (better possible estethics). Higher scores indicate better outcomes.
1 and 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

May 7, 2026

First Submitted That Met QC Criteria

June 28, 2026

First Posted (Actual)

July 6, 2026

Study Record Updates

Last Update Posted (Actual)

July 6, 2026

Last Update Submitted That Met QC Criteria

June 28, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 8328

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wound Healing

Clinical Trials on Periodontal Regenerative Therapy

3
Subscribe